Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association groupMaxime Janin, Elena Mylonas, Véronique Saada, et al.American Journal of Hematology|January 6, 2023
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 studyJean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, et al.Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid DisordersDavid Fandrei, Jean Pegliasco, Florence Pasquier, et al.Journal of Inherited Metabolic Disease|July 30, 2016
A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse modelFang Wang, Jeremy Travins, Zhizhong Lin, et al.ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.Pageof 2